環境，社會 與管治報告 2024 | 目錄 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 關於本報告 | 2 | 關於本公司 | 4 | | | | | | 年度主要榮譽及績效亮點 | 5 | | | | | | | | 管理 | ESG | | | | | | | | 治理架構 | ESG | 8 | | | | | | | 01 | | | | | | | | | 董事會聲明 | 8 | 利益相關方溝通 | 9 | | | | | | 雙重重要性評估 | 10 | | | | | | | | 合規運營 | | | | | | | | | 風險管理與內部控制 | 13 | | | | | | | | 02 | | | | | | | | | 商業道德 | 14 | 信息安全與隱私保護 | 16 | | | | | | 科技倫理 | 17 | | | | | | | | 產品與創新 | | | | | | | | | 研發創新 | 19 | 03 | 知識產權保護 | 24 | | | | | 供應鏈安全 | 25 | ...

Financial Performance - The company reported a revenue of RMB 2,679.67 million for 2024, an increase of RMB 44.76 million, representing a growth of 1.70% compared to the previous year[10]. - Net profit attributable to shareholders was approximately RMB 420.45 million, remaining stable compared to the previous year[10]. - Gross profit for 2024 was RMB 1,868.79 million, with a gross margin of 69.7%[9]. - The company’s net profit margin was 15.6%, slightly down from 15.7% in the previous year[9]. - The company’s basic earnings per share for 2024 was RMB 1.80, compared to RMB 1.75 in 2023[9]. - The overall revenue for the company in the reporting period was approximately RMB 2,679.67 million, an increase of RMB 44.76 million or 1.70% from RMB 2,634.91 million in 2023[59]. - The company's gross profit margin for the reporting period was 69.74%, a slight decrease of 0.60 percentage points from 70.34% in 2023[61]. - Other income and gains for the reporting period amounted to approximately RMB 149.76 million, an increase of about RMB 15.47 million or 11.52% compared to RMB 134.29 million in 2023, primarily due to the recognition of performance compensation from minority shareholders of a subsidiary[62]. Research and Development - Research and development expenses amounted to RMB 238.93 million, an increase of RMB 18.83 million, reflecting a growth of about 8.56% and accounting for 8.92% of total revenue[11]. - R&D expenses for the reporting period were approximately RMB 238.93 million, an increase of about RMB 18.83 million or 8.56% from RMB 220.10 million in 2023, reflecting the company's ongoing investment in expanding its ophthalmology and medical aesthetics product lines[63]. - The company is actively developing advanced artificial lens products, including hydrophobic and hydrophilic extended depth of focus lenses, with clinical trials expected to begin in July 2024[39]. - The company is advancing its research on hydrophilic aspheric multifocal intraocular lenses, with clinical trials completed and registration expected in early 2025[42]. Product Development and Market Expansion - The company successfully launched the globally first organic cross-linked hyaluronic acid product "Hai Mei Yue Bai" in July 2024, and sodium hyaluronate eye drops were approved in March 2024[11]. - The company is expanding its product lines in aesthetic medicine and ophthalmology, with several key projects in clinical trials, including high oxygen permeability scleral lenses[11]. - The group’s hyaluronic acid product line achieved revenue of RMB 737.86 million in 2024, an increase of RMB 138.45 million, representing a growth rate of 23.10% compared to the previous year[28]. - The total revenue from medical beauty and wound care products reached RMB 1,189.22 million, up RMB 136.42 million, with a growth rate of approximately 12.96%[22]. - The company plans to expand the application of hEGF products into various medical fields, including pediatrics and oncology, beyond traditional uses[28]. - The company plans to focus on four rapidly developing treatment areas: medical beauty, wound care, ophthalmology, and orthopedics, emphasizing research and innovation[54]. Market Trends and Competitive Position - The market for non-surgical beauty treatments in China is expected to grow by about 10% in 2024, with a projected compound annual growth rate of 10-15% over the next four years[26]. - The Chinese medical beauty market size grew from RMB 99.3 billion in 2017 to RMB 189.2 billion in 2021, with a compound annual growth rate of 17.5%[24]. - The penetration rate of medical beauty treatments in China is significantly lower than in Brazil, the US, and South Korea, indicating potential for future market growth[24]. - The company achieved a market share increase in the orthopedic sector, rising from 46.54% in 2022 to 50.44% in 2023, solidifying its position as the leading manufacturer of viscoelastic supplements for joint injections in China[46]. Financial Management and Shareholder Returns - The company distributed a total of RMB 166,956,729.00 as final dividends and increased share capital by 66,782,692 shares by the end of July 2024[13]. - For the first half of 2024, the company distributed interim dividends totaling RMB 92,902,248.40[13]. - The board proposed a final dividend of RMB 0.6 per share (before tax) for the year ending December 31, 2024, totaling RMB 138,023,048.4 (before tax) based on the total issued shares of 233,193,695, after accounting for treasury shares[89]. - The company has adopted a dividend policy that emphasizes a balance between reasonable returns to investors and sustainable development[97]. - The company aims for a minimum cash dividend proportion of 80% for mature stages without significant capital expenditure[98]. Regulatory and Compliance - The company emphasizes the importance of environmental protection and has established and continuously improved its environmental management systems, ensuring compliance with pollution discharge standards[85]. - The company has not encountered any significant violations of environmental laws and regulations during the reporting period[85]. - The company has complied with all applicable provisions of the corporate governance code under the Hong Kong Listing Rules during the reporting period[186]. - There are no significant legal proceedings or arbitrations involving the company during the reporting period[187]. Employee and Management Structure - The company had approximately 2,156 employees as of December 31, 2024, with total employee compensation amounting to approximately RMB 692.94 million, an increase of about RMB 62.86 million from the previous year[70]. - The company’s employee compensation policy aims to enhance governance structure and motivate core teams to improve competitiveness[145]. - Non-executive directors receive fixed remuneration based on their background, experience, and responsibilities, with no additional director remuneration for executive directors[144]. Share Repurchase and Capital Management - The company repurchased 1,418,934 A-shares, accounting for 0.61% of total shares, with a total transaction amount of approximately RMB 106.27 million[13]. - A total of 2,492,100 H-shares were repurchased during the year, with a total expenditure of HKD 75,709,045.00[120]. - The board believes that the share repurchase enhances investor confidence and aligns the interests of shareholders, the company, and employees[121]. Governance and Stakeholder Engagement - The company maintains good relationships with stakeholders, including customers, shareholders, government agencies, employees, suppliers, and the community, to achieve medium- and long-term goals[86]. - The company has established a governance structure consisting of the general meeting of shareholders, the board of directors, the supervisory board, and the management team[195].

Shanghai Haohai Biological Technology Co., Ltd. 上海昊海生物科技股份有限公司 (a joint stock company incorporated in the People's Republic of China with limited liability) （於中華人民共和國註冊成立的股份有限公司） (Stock code 股份代號： 6826) 28 April 2025 Dear registered shareholder(s), Reminder letter regarding the Arrangement of Electronic Dissemination of Corporate Communications With reference to the notification letter dated 24 January 2024 titled "Arrangement of Electronic Dissemination of Corporate Communications", Shanghai Haohai Biologi ...

Shanghai Haohai Biological Technology Co., Ltd. 上海昊海生物科技股份有限公司 (a joint stock company incorporated in the People's Republic of China with limited liability) （於中華人民共和國註冊成立的股份有限公司） (Stock code 股份代號： 6826) Dear non-registered shareholder(s), 28 April 2025 Reminder letter regarding the Arrangement of Electronic Dissemination of Corporate Communications With reference to the notification letter dated 24 January 2024 titled "Arrangement of Electronic Dissemination of Corporate Communications", Shanghai Haohai Bio ...

Core Viewpoint - The company, Haohai Biological Technology Co., Ltd., is experiencing a decline in stock price and has a lower price-to-earnings (PE) ratio compared to the industry average, indicating potential undervaluation in the medical device sector [1][2]. Company Summary - Haohai Biological Technology's closing stock price is 54.34 yuan, down 2.34%, with a rolling PE ratio of 30.14 times and a total market capitalization of 12.672 billion yuan [1]. - The company operates in the medical device and pharmaceutical sectors, focusing on the research, production, and sales of products such as ophthalmic viscoelastic devices, artificial lenses, and hyaluronic acid [1]. - For the fiscal year 2024, the company reported revenue of 2.698 billion yuan, a year-on-year increase of 1.64%, and a net profit of 420 million yuan, reflecting a year-on-year growth of 1.04%, with a gross profit margin of 69.88% [1]. Industry Summary - The average PE ratio for the medical device industry is 45.94 times, with a median of 29.64 times, positioning Haohai Biological Technology at the 77th rank within the industry [2]. - The company has 7,605 shareholders as of February 29, 2020, an increase of 918 shareholders, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1].

表格類別： 股票 狀態： 新提交 公司名稱： 上海昊海生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司） 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 A | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | 說明 | A 股（上海證券交易所科創板，股份代號：688366） | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | 已發行股份總數 | | 於下列日期開始時的結存(註1 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海昊海生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司） 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 A | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | 說明 | A 股（上海證券交易所科創板，股份代號：688366） | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 承董事會命 上海昊海生物科技股份有限公司 主席 侯永泰 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6826） 海外監管公告 本公告乃由上海昊海生物科技股份有限公司（「本公司」）根據《香港聯合交易所有 限公司證券上市規則》第13.10B條的規定刊發。 茲載列本公司在上海證券交易所網站刊登之《上海昊海生物科技股份有限公司關 於變更持續督導保薦代表人的公告》，僅供參考。 Shanghai Haohai Biological Technology Co., Ltd.* 上海昊海生物科技股份有限公司 中國上海，2025年4月11日 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海昊海生物科技股份有限公司（以下简称"公司"）于近日收到瑞银证券 有限责任公司（以下简称"瑞银证券"）出具的《瑞银证券有限责任公司关于 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 主席 侯永泰 中國上海，二零二五年四月十一日 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6826） 董事會會議召開日期 上海昊海生物科技股份有限公司（「本公司」）董事會（「董事會」）茲通告謹定於二 零二五年四月二十五日（星期五）舉行董事會會議，藉以（其中包括）審議及通過本 公司及其附屬公司截至二零二五年三月三十一日止三個月之第一季度業績及其發 佈。 承董事會命 上海昊海生物科技股份有限公司 Shanghai Haohai Biological Technology Co., Ltd.* 上海昊海生物科技股份有限公司 於本公告日期，本公司之執行董事為侯永泰博士、吳劍英先生、陳奕奕女士及唐 敏捷先生；本公司之非執行董事為游捷女士及黃明先生；及本公司之獨立非執行 董事為沈紅波先生、姜志宏先生、蘇治先生、楊玉社先生及趙磊先生。 * 僅供識別 ...

证券代码：688366 证券简称：昊海生科 公告编号：2025-016 上海昊海生物科技股份有限公司 关于变更持续督导保荐代表人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本次变更不影响瑞银证券对公司的持续督导工作，公司董事会对罗勇先生在 担任公司保荐代表人期间做出的贡献表示衷心感谢! 特此公告。 上海昊海生物科技股份有限公司董事会 2025年4月12日 附件： 顾承宗先生简历 顾承宗，男，保荐代表人，现任瑞银证券全球投资银行部执行董事，上海交通大 学国际贸易学硕士学位及经济学学士学位，并为注册金融分析师（CFA）三级候 选人。顾承宗先生曾先后参与执行了麦加芯彩15.68亿元A股IPO、前沿生物18.44 亿元A股IPO、春秋航空18.16亿元A股IPO、浦发银行300亿元境内优先股非公开 发行、交通银行298亿元A股非公开发行、南京医药引进联合博姿战略投资人、春 秋航空35亿元A股非公开发行等境内股权融资项目，同时还参与了多家企业的债 券融资项目以及境外股权融资项目。 上海昊海生物科技股份有限公司（以下简称" ...